News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,025 Results
Type
Article (39389)
Company Profile (305)
Press Release (647331)
Section
Business (204793)
Career Advice (2000)
Deals (35477)
Drug Delivery (86)
Drug Development (80980)
Employer Resources (168)
FDA (16116)
Job Trends (14856)
News (345801)
Policy (32547)
Tag
Academia (2550)
Alliances (49405)
Alzheimer's disease (1226)
Approvals (16035)
Artificial intelligence (122)
Bankruptcy (354)
Best Places to Work (11512)
Biotechnology (214)
Breast cancer (112)
Cancer (970)
Cardiovascular disease (82)
Career advice (1669)
Cell therapy (211)
Clinical research (64130)
Collaboration (341)
Compensation (173)
COVID-19 (2539)
C-suite (85)
Data (941)
Diabetes (141)
Diagnostics (6135)
Earnings (84617)
Employer resources (146)
Events (109629)
Executive appointments (256)
FDA (16582)
Funding (304)
Gene therapy (153)
GLP-1 (570)
Government (4337)
Healthcare (18684)
Infectious disease (2618)
Inflammatory bowel disease (105)
Interviews (308)
IPO (16311)
Job creations (3658)
Job search strategy (1427)
Layoffs (414)
Legal (7884)
Lung cancer (158)
Manufacturing (159)
Medical device (13168)
Medtech (13173)
Mergers & acquisitions (19201)
Metabolic disorders (377)
Neuroscience (1472)
NextGen Class of 2024 (6534)
Non-profit (4475)
Northern California (1307)
Obesity (223)
Opinion (180)
Patents (96)
People (56486)
Phase I (19929)
Phase II (28245)
Phase III (21066)
Pipeline (320)
Postmarket research (2554)
Preclinical (8484)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5939)
Regulatory (21529)
Research institute (2315)
Resumes & cover letters (350)
Southern California (1168)
Startups (3614)
United States (12335)
Vaccines (543)
Weight loss (164)
Date
Today (232)
Last 7 days (1068)
Last 30 days (3285)
Last 365 days (35579)
2024 (31278)
2023 (40183)
2022 (51295)
2021 (55843)
2020 (54171)
2019 (46649)
2018 (35135)
2017 (32235)
2016 (31633)
2015 (37715)
2014 (31460)
2013 (26503)
2012 (28779)
2011 (29428)
2010 (27529)
Location
Africa (716)
Arizona (188)
Asia (37264)
Australia (6088)
California (2954)
Canada (1208)
China (225)
Colorado (128)
Connecticut (131)
Europe (79851)
Florida (415)
Georgia (104)
Illinois (323)
Indiana (188)
Kansas (97)
Maryland (544)
Massachusetts (2384)
Michigan (146)
Minnesota (257)
New Jersey (868)
New York (877)
North Carolina (675)
Northern California (1307)
Ohio (131)
Pennsylvania (783)
South America (1094)
Southern California (1168)
Texas (407)
Utah (84)
Washington State (336)
687,025 Results for "upstream biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
Upstream Raises $255M IPO for Inflammatory Drugs; CAMP4 Nets $75M for RNA Work
Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease work, while CAMP4 Therapeutics picked up $75 million to develop RNA-targeting drugs.
October 11, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 8, 2024
·
11 min read
Press Releases
Upstream Bio Announces Pricing of Upsized Initial Public Offering
October 11, 2024
·
3 min read
Genetown
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
Upstream Bio, Inc.today presented clinical data from its dose-ranging study of verekitug (UPB-101) in adults with asthma, at the American Thoracic Society International Conference being held in San Diego, CA.
May 22, 2024
·
5 min read
Press Releases
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 15, 2024
·
2 min read
Genetown
Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference
Upstream Bio , Inc. today announced an upcoming presentation featuring clinical data from its dose-ranging study of verekitug (UPB-101) in adults with asthma, at the American Thoracic Society (ATS).
May 15, 2024
·
3 min read
Business
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
Upstream Bio, a clinical-stage biotech company advancing verekitug for respiratory disorders, announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.
April 2, 2024
·
4 min read
Drug Development
Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients.
March 7, 2024
·
5 min read
Press Releases
Revolo Announces New Data Further Validating the Upstream Mechanism of Action and Subcutaneous Administration of ‘1104
July 25, 2024
·
4 min read
Biotech Bay
Octave® Bioscience, Inc. Announces Publication in Nature Communications
Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
May 29, 2024
·
5 min read
1 of 68,703
Next
